In terms of LGGs, age (≤40 years vs. > 40 years), tumor grade (II vs. III), and IDH status (wild-type vs. mutation) are well-established and widespread prognostic biomarkers in clinical practice (Ricard et al., 2012; Cancer Genome Atlas Research et al., 2015; Zeng et al., 2018; National Comprehensive Cancer Network, 2019). The gene discussed is IDH1; the disease is neoplasm.